the implications of checkmate 650 for the clinical management of post-chemotherapy mcrpc
Published 1 year ago • 20 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
0:50
checkmate 650: nivolumab ipilimumab, ipilimumab alone, or cabazitaxel in mcrpc
-
1:37
novel immunotherapeutic approaches under evaluation in patients with mcrpc
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
3:43
latest from checkmate 650: nivolumab plus ipilimumab for the treatment of metastatic castration-...
-
1:10
treatment options for patients with metastatic castration-resistant prostate cancer
-
1:10
unmet needs in immunotherapy for prostate cancer
-
3:27
improving the prognosis of prostate cancer
-
1:56
dr. subudhi discusses rationale for checkmate-650 study in prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:57
enzalutamide after docetaxel for mcrpc: evaluation by the italian named patient program
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
4:56
improving the prognosis for patients with mcrpc
-
28:36
role of chemotherapy, treatment sequencing in mcrpc and future directions
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer